Research and Development

The headline news from the ABPI’s press conference on Disclosure UK was that healthcare professionals’ (HCPs) disclosure of payments for …

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …

This report from Kalorama Information was featured in the Spring 2017 edition of Pharmafile. Despite new approaches, new technologies and …

It’s Friday, and we’ve brought together our weekly digest of the articles which proved most popular with our readers. Mylan …

The American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have formed a research partnership to reduce the impact …

Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in …

Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …

The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with …

A proof-of-concept study conducted at the Duke Cancer Institute (DCI) in North Carolina has shown that an investigational antibody has …

There are currently no effective treatments for neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease. This is presently a pressing …

The University of Warwick, alongside the University of Manchester, are launching a world-first study aimed at determining the length of …

Simon S Jones has been revealed as the new President and Chief Executive Officer of Regenacy Pharmaceuticals, a biopharma company …

Myeloma UK, the only organisation in the UK dealing exclusively with myeloma, will have a new CEO in place from …

Swiss pharmaceutical manufacturer Lonza has announced that it has been cleared to proceed with its $5.5 billion acquisition of New …